Back to results
US 8,524,749 B2Granted
Controlled release compositions of tizanidine
AssigneeAlza Corporation
InventorsScott Bull, Suneel Gupta, Rhea Donley, Nishit Modi, Noymi Yam
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.
Claims12
A method for treating a patient suffering from spasticity comprising orally administering to the patient an osmotic dosage form comprising a core comprising
- a first layer of tizanidine succinate,
- a second layer of tizanidine succinate, and
- a expandable push layer;
- and
- a semi-permeable membrane,
- wherein the tizanidine succinate is released from the dosage form in manner such that the concentration of tizanidine in the plasma of the patient substantially ascends over a period of 8 hours following administration of the dosage form and the concentration of tizanidine in the plasma of the patient is between 1-4 ng/mL.
3 more elements
An osmotic dosage form comprising
- a core comprising
- a first layer of tizanidine succinate comprising between 5 and 25% of tizanidine succinate,
- a second layer of tizanidine succinate comprising between 75 and 95% tizanidine succinate, wherein the first layer of tizanidine succinate is substantially released within 3 hours of administration of the dosage form and the second layer of tizanidine succinate is substantially released over a period of 1-14 hours of administration of the dosage form, and
- an expandable push layer;
- and
- a semi-permeable membrane,
- wherein the tizanidine succinate is released from the dosage form in manner such that the concentration of tizanidine in the plasma of the patient substantially ascends over a period of 8 hours following administration of the dosage form.
4 more elements
Dependencies are inferred from the claim text.